MedTrace Logo

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

NCT04525859 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-06-24

No results posted yet for this study

Summary

This study will examine the safety and potential effectiveness of poly-ICLC directly injected into malignant pleural mesothelioma at the time of biopsy up to 21 days prior to the cancer being removed by the surgeon

Conditions

  • Malignant Pleural Mesothelioma

Interventions

BIOLOGICAL

Safety

See previous Safety group description

BIOLOGICAL

Expansion Cohort

See previous Expansion Cohort

Sponsors & Collaborators

Principal Investigators

  • Thomas Marron, MD · Assistant Director

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-19
Primary Completion
2025-06-18
Completion
2025-06-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04525859 on ClinicalTrials.gov